1. Lindholm LH, Carlberg B, Samuelsson O. Should beta-blockers remain first choice in treatment of primary hypertension? A meta-analysis. Lancet. 2005; 366: 1545-53.
2. Bradley H, Wiysonge C, Volmink J, et al. How strong is the evidence for use bets-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens. 2006; 24: 2131-41.
3. Lindholm LH, Ibsen T, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint Reduction in hypertension study (LIFE). Lancet. 2002; 359: 1004-10.
4. Zanchetti A, Bond G, Hennig M, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation. 2002; 106: 422-27.
5. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine addingperindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet. 2005; 366: 895-906.
6. Конради А.О. Бета-блокаторы в лечении артериальной гипертензии - наступило ли время забвения? Артериальная гипертензия. 2006;12(3): 212-15.
7. Lopez-Sendon J., Swedberg K., McMurray J. et al. Expert consensus document on β-adrenergic receptor blockers. The Task Force on Beta-Blockers of the European Society of Cardiology. Eur Heart J. 2004; 25: 1341-62.
8. Сычева Д.А., Раменская Г.В., Игнатьев И.В. и соавторы. Клиническая фармакокинетика бета-адреноблокаторов: возможности повышения эффективности и безопасности терапии. Сердце. 2006; 5 (3): 162-65.
9. Затейщиков Д.А., Минушкина Л.О., Савельева Е.Г. Бетаксолол: вопросы и ответы. Фарматека. 2006; №8: 1-5.
10. Cohen D.L., Townsend R.R. Update on β-blockers in hypertension. J Clin Hypertens. 2006; 8:899-900.
11. Wilkinson IB, McEniery CM, Cocroft JR. Atenolol and cardiovascular risk: an issue close to the heart. Lancet. 2006; 367:627-29.
12. Poole- Wilson PA. COMET study. European Congress of Cardiology. Vienna, September 2003.
13. Prichard BN. Β-blocking agents with vasodilating. J Cardiovasc Pharmacol. 1992; 19: S1-S4.
14. Dhein S, Titzer S, Wallstein M, et al. Celiprolol exerts microvascular dilatation by activation of β2-adrenoreceptors. Naunyn-Schmiedeberg's Arch Pharmacol. 1992; 346: 27-31.
15. Giannattasio C, Cleroux J, Seravalle G, et al. Effects of dilevalol on forearm circulation in essential hypertension. Am J Cardiol. 1989; 63: 21I-24I.
16. Setoguchi M, Ohya Y, Abe I, Fujishima M. Inhibitory action of betaxolol, a β1-selective adrenoceptor antagonist, on voltage-dependent calcium channels in guinea-pig artery and vein. Br J Pharmacol. 1995; 115: 198-202.
17. Kakoki M, Hirata Y, Hayakawa Y, et al. Effects of vasodilatory β-adrenoceptor antagonists on endothelium-derived nitric oxide release in rat kidney. Hypertension. 1999; 33: 467-71.
18. Kobayashi N, Yoshida K, Mita S. Betaxolol stimulates eNOS production associated with LOX-1 and VEGF in Dahl salt-sensitive rats. J Hypertens. 2004; 22: 1397-402.
19. Wenzel S, Rohde C, Wingerning S, et al. Lack of endothelial nitric oxide synthase-derived nitric oxide formation favors hypertrophy in adult ventricular cardiomyocytes. Hypertension. 2007; 49: 193-200.
20. Jaillard J, Rouffy J, Sauvanet J et al. Long-term influence of betaxolol on plasma lipids and lipoproteins. In Morselli et al. L.E.R.S.Monograph. New York, Raven Press. 1983; 221-31.
21. Brugmann U, Blassini R, Rudolph W et al. Comparative effects of long-acting beta-adrenergic receptor blockers with and without cardioselectivity: double-blind randomized cross-over and placebo-controlled study of betaxolol and nadolol. Circulation. 1983; 68: Suppl III: 406.
22. Davies I, Larribaut J, Thiercelin J, et al. Betaxolol does not modify hypoglycemic actions on glibenclamide or metformine in normal subjects. Br J Clin Pharmacol. 1984; 17:622P
23. Van Os, Van Brummeneisen P, Woitteis AJJ. Betaxolol on obese hypertensive patients Long-term effects on blood pressure and serum lipids. Neth J Med. 1991; 40: 227-31.
24. Benn JJ, Broun PM, Beckwith LJ. Glucose turnover in type I diabetic subjects during exercise. Diabetes Care. 1992; 15: 4-6.
25. Быстрова М.М., Бриттова А.Н., Горбунов Ю.М. и соавторы. Лечение артериальной гипертензии бетаксололом у женщин в постменопаузе. Терапевтический архив. 1999; 71(6): 67-69.
26. Шляхто Е.В., Трешкур Т.В., Капанадзе С.Т. Когда бета-адреноблокаторы являются препаратами выбора в лечении желудочковых аритмий? Артериальная гипертензия. 2006; 12(2):149-55.
27. Метелица И.И. Справочник по клинической фармакологии сердечно-сосудистых средств. М. «Медпрактика». 1996. с.123-52.
28. Новикова Т.Н., Заварицкая О.П. Применение локрена как антиаритмического препарата в практике работы центра кардиотелеметрии. Тезисы юбилейной научно-практической конференции «Современные возможности профилактики, диагностики и лечения заболеваний сердечно-сосудистой системы», посвященной 40-летию основания отделения кардиологии НУЗ Дорожной клинической больницы ОАО «Российские железные дороги». СПб. 2005. с.32-33.
29. Irvine NA, Lipworth BJ, McDevitt DC. A dose-ranging study to evaluate the beta-adrenoceptor selectivity of single doses of betaxolol. Br J Clin Pharmacol. 1990; 30: 119-26.
30. Johnson BF, Whelton AA. Study design for comparing the effect of missing daily doses of antihypertensive drugs. Am J Ther. 1994; 1:260-67.
31. Lee JY, Kusek JW, Greene PG et al. Assessing medication adherence by pill count and electronic monitoring in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Am J Hypertension. 1996; 9: 719-25.
32. Hosie J, Wiklund I, Managing hypertension in general practice: can we do better? J Hum Hypertens. 1995; 9: S15-S18.
